We seek opportunities to enhance our patients’ futures

At Intercept, our mission is to translate bile acid research into promising new treatments for liver diseases.

Commitment that REVITALIZES

Rejuvenating tomorrow starts with commitment today. That’s why we’re working closely with patients and caregivers to ensure they have ample resources to navigate options.

Commitment that REVITALIZES

Rejuvenating tomorrow starts with commitment today. That’s why we’re working closely with patients and caregivers to ensure they have ample resources to navigate options.

Discovery Compounds

INT-767: an orally administered second generation agent with potent dual activity against farnesoid X receptor (FXR) and TGR5, a G-protein coupled bile acid receptor

  • INT-767 is Intercept’s second bile acid analog to enter phase 1 clinical development
  • INT-767 is a more potent FXR agonist than obeticholic acid (OCA), Intercept’s lead product candidate, and has the potential to demonstrate greater efficacy in liver disease
  • INT-767 also activates TGR5, a second bile acid receptor. TGR5 has been shown to affect energy metabolism, glucose homeostasis, bile composition/secretion, and inflammation
  • In animal models, INT-767 has shown the potential to both prevent and reverse organ damage due to fibrosis

INT-777: an orally administered selective TGR5 agonist

In animal models of diabetes, treatment with INT-777 induced glucagon-like peptide-1 (GLP-1) secretion.

  • In vitro studies demonstrate that INT-777 selectively targets TGR5 with no effects on a broad range of other receptors
  • Activation of TGR5 is directly linked to release of GLP-1 in the intestine, and INT-777 has the potential to improve
    • Liver steatosis, fibrosis, and blood lipid levels
    • Insulin sensitivity
    • Glycemic control

You are now leaving interceptpharma.com


You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.

Close this window to return to Intercept Pharma’s site or click ‘Continue’ to proceed. 

You are now being redirected to Intercept's job application site, hosted by a third party.